warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
MedImmune D5760C00001: A Phase 1 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI4276 in Subjects with Select HER2-expressing Advanced Solid Tumor
Brief Description  
The primary objective is to assess the safety, describe the DLTs, and determine the MTD or the maximum administered dose (MAD; in the absence of exceeding the MTD) for MEDI4276 administered as a single agent in subjects with HER2-expressing advanced breast or gastric cancer refractory to standard therapy or for which no standard therapy exists.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Breast
Status  
OPEN
Start Date  
04/28/2016
IRB Number  
00016397
Principal Investigator  
Tan, Antoinette Roslyn
Contact Name  
Tesa M Adams

For More Information, Contact  Tesa  M, Adams
Phone:  980-442-2335 Fax:    
Email:  Tesa.Adams@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, NC 28204
Close